Haemonetics has delivered a strong run in recent years, so the obvious question for anyone looking at the stock today is whether the current share price still lines up with the cash the business is expected to generate. With the market now pricing Haemonetics at recent levels around US$119.93, the focus naturally shifts to what its cash flows can support over time.
-
Over the past 5 years the stock has returned 100.0%, which puts real weight on whether that share price performance is backed by durable cash generation.
-
The group's medical technology model relies on turning procedure volumes and equipment placements into recurring cash inflows, which can shape both the amount and timing of the cash available to equity holders.
-
If you'd rather focus on earnings, this one's for you. See why Haemonetics's 52.5x P/E tells a different valuation story .
The issue now is whether Haemonetics' current valuation is adequately supported by the cash flows implied by a Discounted Cash Flow (DCF) view.
To see how Haemonetics compares with other companies where cash generation and valuation are in focus, line it up against 39 high quality undervalued stocks
Does Haemonetics Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) model here is built around what Haemonetics can return to shareholders through future free cash flows. On the latest twelve month numbers, the group generated about $305.5 million of free cash flow, which is a meaningful base for a business priced at US$119.93 per share today.
Analyst projections in the DCF point to free cash flow that continues to grow from this starting point, with the long range forecasts gradually easing to mid single digit annual increases. The pattern looks more like a mature medtech operation expected to add incremental cash each year rather than a turnaround story or a sharp contraction. When those projected streams are discounted back, the DCF output indicates Haemonetics' estimated intrinsic value is substantially above the current share price, which suggests the market is not fully reflecting the cash flows implied by this model yet. Find out what Haemonetics could be worth using our Discounted Cash Flow (DCF) estimate .
The Haemonetics Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the DCF puzzle leaves off. They show which paths for Haemonetics' growth, margins and earnings would need to hold for the stock to be worth materially more or materially less than today's price on the Community page. Each narrative links a fair value estimate to a specific storyline about Haemonetics' potential catalysts and key risks, so you can track over time which version of events appears to be unfolding.
Haemonetics draws a split crowd, with one camp seeing solid cash power already in the price and the other more focused on contract terms and rising costs.
Bull case: roughly fairly valued
"Bullish analysts highlight that the expanded CSL agreement could be "transformative" for Haemonetics, with cited upside figures of about $400 million in sales and $2.35 in adjusted earnings per share…"
Discover why this Narrative puts Haemonetics at roughly fairly valued .
Bear case: 38% overvalued
"Although Haemonetics has a non exclusive U.S. supply agreement that may allow CSL Plasma to adopt NexSys PCS with Persona PLUS and related disposables, the absence of minimum purchase commitments and the lack of guidance updates on scope or timing introduce a risk that actual order volumes trail current expectations…"
Explore why this Narrative puts Haemonetics at 38% overvalued .
Haemonetics' share price is only one piece of the decision
Before making any call on Haemonetics, you also need to know who is steering the business, how their incentives are set up, and whether those rewards line up with your interests. See who runs Haemonetics and how they are paid .
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include HAE .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
